Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Fineline Cube Jul 17, 2026
Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Fineline Cube Jul 17, 2026
Company Drug

Roche’s Genentech Gets Green Light for Vixarelimab UC Clinical Trial in China

Fineline Cube May 24, 2024

Roche (SWX: ROG)’s Genentech, a leading biotechnology company based in Switzerland, has received approval to...

Company Drug

RemeGen’s Disitamab Vedotin on Track for Breakthrough Designation in Muscle Invasive Bladder Cancer

Fineline Cube May 24, 2024

RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced that its antibody-drug...

Policy / Regulatory

Guangzhou Boosts Innovative Drug Development with New HSA Initiatives

Fineline Cube May 24, 2024

The Healthcare Security Administration (HSA) bureau in Guangzhou’s province has issued a notification outlining measures...

Company Drug

Gan & Lee Pharmaceuticals Gains Marketing Approval for Insulin Glargine in Mexico

Fineline Cube May 24, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Company Deals

China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition

Fineline Cube May 24, 2024

Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with...

Company Drug

Keymed Biosciences’ Stapokibart Earns Priority Review for Chronic Sinusitis Treatment in China

Fineline Cube May 24, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced that its...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Shows Positive Results in RCC Combination Therapy Study

Fineline Cube May 24, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced positive...

Company Deals

Boehringer Ingelheim and Peking University Deepen Partnership with Joint Drug Research Lab

Fineline Cube May 24, 2024

Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking...

Company Deals

Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals

Fineline Cube May 23, 2024

Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a...

Company Deals

MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment

Fineline Cube May 23, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda...

Company Deals

Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03

Fineline Cube May 23, 2024

Amgen’s (NASDAQ: AMGN) dominance in the bone treatment market with its blockbuster drugs Xgeva and...

Company Deals

Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement

Fineline Cube May 23, 2024

China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement...

Policy / Regulatory

China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations

Fineline Cube May 23, 2024

The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...

Company

Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary

Fineline Cube May 23, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans...

Company Drug

Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...

Company Drug

Simcere Pharmaceutical’s Quviviq Secures Hong Kong Marketing Approval for Insomnia Treatment

Fineline Cube May 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval...

Company Drug

NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment

Fineline Cube May 23, 2024

NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...

Company Deals Digital

C.Q. Pharmaceutical and JD.com Join Forces to Revolutionize Pharmaceutical Supply Chain

Fineline Cube May 23, 2024

C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a prominent Chinese pharmaceutical company, has announced a...

Company Deals

AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement

Fineline Cube May 23, 2024

HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...

Company Deals

Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in...

Posts pagination

1 … 386 387 388 … 696

Recent updates

  • Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression
  • Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy
  • Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs
  • Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients
  • Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Company Drug

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.